Citius Oncology (NASDAQ:CTOR) Posts Earnings Results, Meets Expectations

Citius Oncology (NASDAQ:CTOR) announced its quarterly earnings results on Friday. The company reported ($0.06) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.06), FiscalAI reports. The firm had revenue of $3.94 million for the quarter, compared to the consensus estimate of $4.37 million.

Citius Oncology Trading Up 2.6%

Shares of Citius Oncology stock traded up $0.03 on Friday, hitting $1.21. The stock had a trading volume of 145,894 shares, compared to its average volume of 223,311. The stock has a 50 day moving average of $1.12 and a 200 day moving average of $1.51. The firm has a market capitalization of $106.91 million, a P/E ratio of -3.57 and a beta of 3.09. Citius Oncology has a twelve month low of $0.55 and a twelve month high of $6.19. The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.11 and a current ratio of 0.56.

Institutional Investors Weigh In On Citius Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC bought a new position in shares of Citius Oncology in the third quarter valued at $36,000. Bank of America Corp DE boosted its stake in Citius Oncology by 5,256.9% during the 2nd quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock valued at $37,000 after purchasing an additional 8,411 shares during the last quarter. Geode Capital Management LLC increased its holdings in Citius Oncology by 31.6% during the 4th quarter. Geode Capital Management LLC now owns 220,047 shares of the company’s stock worth $220,000 after purchasing an additional 52,875 shares in the last quarter. Jane Street Group LLC purchased a new stake in Citius Oncology in the 2nd quarter valued at $465,000. Finally, Armistice Capital LLC purchased a new position in Citius Oncology during the 3rd quarter worth $15,582,000. 70.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Citius Oncology in a research note on Monday, December 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $6.00.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.